United Therapeutics AI Stock Analysis
Want to see UTHR full AI Analyst Report?
United Therapeutics (UTHR) AI Stock Analysis
United Therapeutics
(NASDAQ:UTHR)
UTHR scores highly primarily due to outstanding financial strength (premium margins, strong cash generation, and effectively no debt) and a strong technical setup with price above all major moving averages. The score is moderated by slowing top-line growth and weaker recent free-cash-flow trend, plus regulatory/execution timing risks highlighted on the earnings call (notably the delayed soft mist inhaler filing and ralinepag supply-chain compliance issue).
United Therapeutics Key Performance Indicators (KPIs)
Revenue by GeographyShows where United Therapeutics earns its sales and highlights dependence on key markets—typically the U.S. versus international regions—so you can judge how sensitive revenue is to U.S. reimbursement decisions, regional regulatory shifts, and currency moves. A heavy U.S. skew signals vulnerability to domestic pricing and payer actions, while growing ex‑U.S. sales point to new patient pools and diversification of risk.
International revenue has been lumpy but just staged a meaningful rebound to near‑record levels, indicating the doubled sales force and record starts/referrals are beginning to translate abroad. That suggests commercial investments can drive outsized upside, but revenue often lags patient metrics and nebulized Tyvaso faces rising competition, so sustainability depends on upcoming regulatory wins (Tyvaso IPF, ralinepag and device filings) and execution on launches; absent those catalysts the international uptick could prove transient.
United Therapeutics (UTHR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $25.04B
- Dividend Yield
- ―
- Average Volume (3M)
- 694.95K
- Price to Earnings (P/E)
- 20.5
- Beta (1Y)
- 0.50
- Revenue Growth
- 1.89%
- EPS Growth
- 0.33%
- Country
- US
- Employees
- 1,400
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
United Therapeutics Business Overview & Revenue Model
Company Description
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both th...
How the Company Makes Money
United Therapeutics makes money primarily by selling branded prescription medicines, with its core revenue derived from PAH therapies. Key revenue streams include: (1) Product sales of PAH medicines in the U.S. and internationally, sold through speci...
United Therapeutics Earnings Call Summary
The call was strongly positive, led by record total and Tyvaso revenue, improving referral and demand trends, favorable intellectual property and settlement developments, and confidence in a broad pipeline and upcoming launches. The main negatives were execution and regulatory timing issues, including the delayed soft mist inhaler filing, the ralinepag API supplier’s OAI status, uncertainty around the triple oral pill filing path, and moderate near-term patient switching expectations.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management expects near-term transitions from YUTREPIA to Tyvaso to be moderate, with a PH-ILD referral inflection expected over the next couple weeks, and into December, and then obviously the first part of the year, followed by a new baseline in referrals over the next few weeks; it expects to submit the soft mist inhaler NDA in 2027 and not at the end of this year, while oral ralinepag has a PDUFA date of June 24 of next year. Management also expects nebulized Tyvaso in IPF and ralinepag in PAH to become multi-billion dollar growth drivers, expects to enter 2027 with substantially more momentum than entering 2026, and reported $833 million of third-quarter total revenue, $504 million of Tyvaso revenue, over 1,000 referrals in October, and that one in three patients starting TYVASO DPI since the introduction of higher-strength cartridges achieved higher doses, twice as what it was beforehand.
United Therapeutics Financial Statement Overview
Summary
Financials are high-quality: very strong profitability (TTM gross margin ~86%, EBIT margin ~50%, net margin ~42%) and an exceptionally conservative balance sheet with effectively no debt (Total Debt: $0 TTM). Cash generation remains strong (TTM operating cash flow ~$1.43B), but the score is tempered by decelerating growth (TTM revenue ~1%) and a meaningful decline in TTM free cash flow (down ~21% to ~$867M).
Income Statement
92Very PositiveBalance Sheet
95Very PositiveCash Flow
80Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.19B | 3.18B | 2.88B | 2.33B | 1.94B | 1.69B |
| Gross Profit | 2.75B | 2.80B | 2.57B | 2.07B | 1.79B | 1.56B |
| EBITDA | 1.58B | 1.82B | 1.65B | 1.39B | 1.04B | 736.80M |
| Net Income | 1.23B | 1.33B | 1.20B | 984.80M | 727.30M | 475.80M |
Balance Sheet | ||||||
| Total Assets | 7.03B | 7.88B | 7.36B | 7.17B | 6.04B | 5.17B |
| Cash, Cash Equivalents and Short-Term Investments | 2.07B | 1.56B | 3.27B | 2.99B | 2.84B | 1.93B |
| Total Debt | 0 | 37.60M | 300.00M | 700.00M | 800.00M | 800.00M |
| Total Liabilities | 758.10M | 783.80M | 920.00M | 1.18B | 1.25B | 1.21B |
| Stockholders Equity | 6.28B | 7.10B | 6.44B | 5.98B | 4.80B | 3.96B |
Cash Flow | ||||||
| Free Cash Flow | 867.20M | 1.04B | 1.08B | 747.60M | 663.70M | 477.40M |
| Operating Cash Flow | 1.43B | 1.56B | 1.33B | 978.00M | 802.50M | 598.20M |
| Investing Cash Flow | 93.00M | -551.30M | 417.20M | -719.60M | -811.50M | -486.90M |
| Financing Cash Flow | -1.67B | -1.15B | -1.25B | -11.90M | 75.40M | 44.80M |
United Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTHR, the sentiment is Positive. The current price of 587.88 is above the 20-day moving average (MA) of 586.26, above the 50-day MA of 544.61, and above the 200-day MA of 538.05, indicating a bullish trend. The MACD of 11.88 indicates Positive momentum. The RSI at 56.40 is Neutral, neither overbought nor oversold. The STOCH value of 59.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTHR.
United Therapeutics Risk Analysis
United Therapeutics disclosed 32 risk factors in its most recent earnings report. United Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksUnited Therapeutics Peers Comparison
Overall Rating
UTHR85Outperform
ALNY70Outperform
JAZZ66Neutral
INSM65Neutral
BMRN56Neutral
BBIO53Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 85Outperform | $25.04B | 20.54 | 19.18% | ― | 1.89% | 0.33% | |
| 70Outperform | $21.39B | 7.82 | 159.72% | ― | 56.17% | 6459.20% | |
| 66Neutral | $15.39B | 67.29 | 4.62% | ― | 13.48% | ― | |
| 65Neutral | $26.96B | -43.68 | -82.75% | ― | 239.97% | 54.44% | |
| 56Neutral | $11.23B | -645.55 | -0.31% | ― | 19.76% | -103.57% | |
| 53Neutral | $15.07B | -25.44 | 26.76% | ― | 167.27% | 27.40% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| UTHR | United Therapeutics Corp. | 587.88 | 111.34 | 23.36% | |
| ALNY | Alnylam Pharmaceuticals | 159.73 | -301.03 | -65.33% | |
| BMRN | Biomarin Pharmaceutical Inc. | 57.99 | 5.43 | 10.33% | |
| INSM | Insmed | 122.88 | -80.68 | -39.63% | |
| JAZZ | Jazz Pharmaceuticals | 239.77 | 63.69 | 36.17% | |
| BBIO | Bridgebio Pharma | 77.36 | 11.82 | 18.03% |
United Therapeutics Corporate Events
United Therapeutics Announces $2 Billion Share Buyback
PositiveOn October 21, 2026, United Therapeutics Corporation’s board approved a new share repurchase program authorizing the buyback of up to $2 billion of its common stock over a one-year period ending October 21, 2027. The move, announced publicly on Octob...
United Therapeutics Reaches Major Pulmonary Hypertension Settlement
PositiveOn October 13, 2026, United Therapeutics entered a settlement agreement with Liquidia Technologies that will resolve multiple patent and trade secret disputes over inhaled treprostinil products, including UT’s Tyvaso DPI and Liquidia’s Yutrepia. Liqu...
United Therapeutics Announces New Accelerated Share Repurchase
PositiveOn September 8, 2026, United Therapeutics entered into an accelerated share repurchase agreement with Citibank to buy back approximately $477.6 million of its common stock, using the remaining portion of its previously authorized $2 billion share rep...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
